Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.
Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.
A hybrid vector for ligand-directed tumor targeting and molecular imaging.
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.